Please login to the form below

Not currently logged in
Email:
Password:

AZ's Brilinta approved in Canada

Health Canada has approved AstraZeneca's Brilinta to prevent blood clots in patients with acute coronary syndrome

Health Canada has approved AstraZeneca's (AZ) Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events, such as blood clots, in patients with acute coronary syndrome.

The approval comes seven months after the drug was denied approval by the US Food and Drug Administration (FDA), with studies demonstrating that patients were more likely to experience heart problems with Brilinta than rival drug Plavix (clopidogrel), despite AZ's treatment having greater efficacy.

The FDA did not request additional studies, but did ask for additional analyses of the data from the company's PLATO trial. The drug remains in review in the US, as well as Russia, India and China.

Including Canada, Brilinta has now been approved in 33 countries, including in the European Union under the name Brilique.

1st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics